Oruka Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of Oruka Therapeutics with a Buy rating and $49 price target The firm views the rapid uptake of Bimzelx in psoriasis since U.S. approval in 2023 as “clear empirical evidence that raising an already high bar drives meaningful demand” and in that context says that Oruka’s approach to even greater innovation includes building upon the “two best targets to date in psoriasis,” ORKA-001 and ORKA-002. There remains potential for additional upside to the firm’s model for ORKA-002 outside psoriasis, the analyst added.